

## **Alpha-2-Adrenoceptor agonists in Veterinary practice**

Mogoa, E.G.M; Mbithi, Peter Mulwa F; Nguhiu, J.M; Kihurani, D

Date: 2001

### **Abstract**

Since the first  $\alpha$ -adrenoceptor agonist xylazine (Rompun) was synthesized in 1962 in Germany, and the subsequent development of others in this group,  $\alpha$ -adrenoceptor agonists have been used for decades for their sedative, analgesic and muscle relaxant properties in laboratory, domestic and wild animal species. Although drugs in this group induce physiologic alterations in many species whose magnitude depends on the dose, rate of administration, route of administration and, concomitantly administered drugs, they have proven to be safe adjunctive agents in augmenting central nervous system depression, analgesia and muscle relaxation in healthy patients. One of the more significant advances in veterinary anaesthesiology during the last decade has been the utilization of  $\alpha$ -antagonists for the reversal of injectable anaesthetic regimens. Most notable of these is the clinical application of  $\alpha$ -antagonists such as yohimbine, tolazoline, idazoxan, and atipamezole for reversal of the sedative-muscle relaxant actions induced by xylazine and other  $\alpha$ -adrenoceptor agonists. This advance has made the use of drugs in this group safer and they will continue to play an important role in the evolution and development of reliable synergistic receptor-mediated analgesia and anaesthesia. This paper looks at the role  $\alpha$ -adrenoceptor agonists have played and continue to play in veterinary practice.